NCT06743009Completed
Metabolic Effects of the Exercise-metabolite Lac-Phe
The Metabolic Effects of the Exercise-metabolite N-lactoyl-phenylalanine (Lac-Phe)
Source: ClinicalTrials.gov · Last updated 27 Mar 2026
Brief summary (registry, in English)
The goal of this double-blinded, randomized cross-over clinical trial is to assess the isolated (i.e. outside the context of exercise) effects of Lac-Phe on appetite and glucose concentrations in healthy volunteers with obesity (BMI 28-35). The main questions it aims to answer are: * Does Lac-Phe reduce appetite in humans? * Does Lac-Phe have glucose-lowering properties in humans? During the study, participants will: * receive an intravenous infusion of Lac-Phe on one study day and a NaCl infusion on another study day. * drink a standard mixed meal * eat an ad libitum meal test * answer appetite questionnaires * indirect calorimetry * blood samples for hormone and substate analyses
- Status (registry)
- Completed
- Study type
- Interventional
- Enrollment
- 23 (actual)
- First submitted
- 16 Dec 2024
- Start date
- May 2025
- Primary completion date
- Mar 2026
- Lead sponsor
- University of Aarhus
- Diseases
- Obesity
- NCT number
- NCT06743009
What you commit to
- Study type: Interventional
- Participants enrolled: 23
- From May 2025 to the primary completion date, Mar 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Diabetes
- Ongoing cancer or other acute/chronic serious diseases (PI will determine)
Lab values
- Medications affecting glucose metabolism (e.g., Saxenda).
Other
- Anemia
- Inability to understand Danish or English
- Deemed unsuitable to participate by the PI and co-investigators.
Who the study is looking for
- A body mass index (BMI) between 28-35 kg/m2
- Older than 18 years of age
- Hgb within a normal range (females: 7.3-9.5 mmol/L, males: 8.3-10.5 mmol/L)
- Females can be included if they are either postmenopausal or actively use hormonal contraception (e.g., oral contraceptive pill or hormone-releasing intrauterine device).
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| SDCA research laboratory Coordinator of this site? Confirm its status | Aarhus N | Denmark | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.